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Sumary bThe morbidity of high-dose chemotherapy has been considerably reduced by the use of autologous
peripheral blood progenitor cell reinfusion. Most studies have used myeloid colony-stimulating factors after
stem cel reinfusion, making it difficult to determine the relative contribution of each of these variables to the
early recovery of blood ceUls. The financial implications ofcolony-stimulating factor use are an area of concern
as dose intensification in chemosensitive malignancies is increasingly employed. We have studied 19 con-
secutive patients receiving high-dose chemotherapy with and without filgrastim (Amgen, granulocyte colony-
stimulating factor, G-CSF) after stem ceUl infusion to examine its effect on the kinetics of blood cell recovery,
the complications of myelosuppression and the associated costs. Analysis of the two treatment groups reveals
that administration of filgrastim l10g kg-' day-' following stem cell reinfusion does not further accelerate
haemopoietic recovery, fails to reduce the incidence of neutropenic fever or antibiotic usage and significantly
increases the cost of the procedure. The results of this study do not support the routine use of filgrastim after
high-dose chemotherapy and peripheral blood stem cell reinfusion.
The reinfusion of peripheral blood stem cells (PBSCs) follow-
ing high-dose chemotherapy to accelerate haemopoietic
reconstitution is now standard practice in many centres
(Gianni et al., 1990; Kessinger & Armitage, 1991; Sheridan et
al., 1992). Several groups have reported reduced durations of
thrombocytopenia with PBSC rescue compared with autolo-
gous bone marrow transplantation. There have, however,
been some reports of patients with acute myeloid leukaemia
(AML) receiving purged bone marrow having better disease-
free survival than those receiving peripheral stem cell auto-
grafts (Korbling et al., 1991). It is important to administer
sufficient stem cells for engraftment and most centres now
recognise a threshold number of reinfused colony-forming
unit-granulocyte/macrophage (CFU-GM) cells kg-' to
ensure haemopoietic reconstitution (To et al., 1986; Reiffers
et al., 1988). Myeloid colony-stimulating factors (CSFs),
alone or in combination with chemotherapy, are extensively
used to aid harvesting ofadequate numbers ofPBSCs (Duhr-
sen et al., 1988; Siena et al., 1989; Socinski et al., 1988).
Although most centres continue CSF administration after
PBSC infusion, there remains considerable doubt about the
value of myeloid CSFs in this setting in terms of further
accelerating haemopoietic recovery and thus reducing the
morbidity and mortality of the procedure. We have recently
audited a group of 19 consecutive patients undergoing high-
dose chemotherapy between 1991 and 1993 and retrospec-
tively compared the clinical characteristics of patients who
received filgrastim (G-CSF, Amgen) after PBSC reinfusion
with those who did not.
Table I Characteristics of 19 patients receiving high-dose chemotherapy and peripheral blood stem cell rein-
fusion
Condtioning Bone marrow CD34 x 10' kg- I CFU-GM x 10' kg-
Patient Age Sex Diagnosis regimen reinfrrion reinfused reinfirsed
Filgrastim after PBSC reinfusion
1 22 M Hodgkin's EAM Yes 2.5 3.8
2 38 F Non-Hodgkin's EAM Yes 2.7 4.0
3 23 M Non-Hodgkin's TBI/CTX Yes 4.3 3.0
4 23 M Non-Hodgkin's TBI/CTX Yes 5.0 5.9
5 33 F Non-Hodgkin's TBI/CTX Yes 2.6 2.3
6 39 F Teratoma CEC Yes 6.5 6.6
7 31 M Teratoma CEC Yes 6.7 Contaminated
8 29 M Teratoma CEC Yes 5.1 3.2
9 44 M Non-Hodgkdn's BEAM Yes 10.0 10.0
10 16 M Sarcoma TBI/M No 9.1 10.4
Nofilgrastin after PBSC reinfusion
11 31 M Non-Hodgkin's TBI/CTX No 2.4 3.1
12 53 M Non-Hodgkin's TBI/CTX No 2.4 8.0
13 44 M Non-Hodgkin's TBI/CTX No 6.2 9.0
14 62 F Non-Hodgkin's EAM No 10.1 13.1
15 27 M Teratoma CEC No 9.9 20.0
16 45 M Non-Hodgkin's EAM Yes 26.7 17.0
17 39 F Non-Hodgkin's EAM No 8.1 17.0
18 52 F Non-Hodgkin's EAM No 11.3 13.0
19 29 M Teratoma CEC No 6.4 20.9
Conditioning regimens: BEAM, BCNU 300mgm-2, etoposide 1,200mgm-2, cytosine arabinoside 800mg m 2,
melphalan 140mgm2; EAM, etoposide 1,200 mg m-2, cytosine arabinoside 800mgm-2, melphalan 140mgm-2;
CEC, carboplatin AUC x 20, etoposide 1,600mgm2, cyclophosphamide 60mgkg-'. TBI/CTX, total body
irradiation 14.4 Gy, cyclosphosphamide 3.6 gm2; TBI/M, total body irradiation 14.4 Gy, melphalan 140mg m2.
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Patients and methods
The patients selected for high-dose consolidation chemo-
therapy had testicular teratoma (5), non-Hodgkin and Hodg-
kin's lymphoma (12), myeloma (1) and sarcoma (1), and had
received conventional dose induction chemotherapy prior to
high-dose chemotherapy. Patient details are listed in Table I.
There were 14 males and five females, who ranged in age Q,
from 16 to 62 years. A number of patients also received
a
autologous bone marrow reinfusion (ABMR). Different con-
ditioning regimens were used as appropriate for different
tumour types. PBSC harvests were carried out on a Cobe
Spectra following patient priming with conventional chemo-
therapy and filgrastim 5tLgkg- day-' subcutaneously from
the time of the white cell nadir for 5 days. On the 2 days of
leucopheresis they received filgrastim 10jigkg-'day-'. Fol- E
lowing myeloablative chemotherapy all patients received a
PBSC reinfusion containing haemopoietic progenitors in
excess of our recognised threshold values for marrow rescue <
(2 x 105 GFU-GM cellskg-' and 1 x 106 CD34+cellskg-')
C
(Table I). Ten patients received filgrastim 10jgkg-'day-' E
subcutaneously or intravenously from day 5 following stem
cell reinfusion until the neutrophil count was > 1.0 x 9-'.
End point analysis included days of neutrophils <0.5 x
10' 1'- , days of neutrophils <1.0 x 1091', days of platelets
<15 x 1091'- , platelet transfusions, febrile days (temperature
<38°C on two separate occasions in a 24 h period), days on
intravenous antibiotics, cost of intravenous antibiotics,
0
number of in-patient days and overall cost of the procedure.
Statistical methods applied to the results included the
Mann-Whitney U-test to compare median parameters in
each group and calculation of the Spearman rank correlation
coefficient. 0
1._ 0
Results
The initial ten patients received autologous bone marrow in
addition to PBSC, but as confidence in PBSC rescue in- .0 creased bone marrow harvests were discontinued. The addi- o u
tion ofautologous bone marrow reinfusion to PBSC did not E E
lead to more rapid haemopoietic reconstitution than PBSC
reinfusion alone (95% CI for the difference between median X
number of days to engraftment -3.0 to 9.0 days, Mann-
Whitney U-test, P-value 0.285). No correlation between dose
of CFU-GM cellskg-' and rate of engraftment was estab-
lished (Spearman rank correlation coefficient -0.208). Ten
patients (mean age 29.8 years) received filgrastim 10jLg
kg-' day-' s.c. or i.v. daily from day 5 after progenitor cell o
reinfusion until peripheral blood neutrophil counts were E
> 1.0 x 1091-. Nine patients (mean age 42.2 years) received U
peripheral blood stem cell reinfusion alone (Table I). Patients
in the cohort receiving filgrastim were on average reinfused
fewer CFU-GM cellskg-' (5.46 x 10cellskg-' vs 13.4 x
I05cells kg-' reinfused, 95% CI for difference between
median number of CFU-GM kg-' infused -3.00 to -13.5,
Mann-Whitney U-test, P-value 0.0062). There was no U
significant difference between mean numbers of CD34+cells
kg-' reinfused in each treatment group (9.32 ± 2.1 x 106
cells kg-' vs 9.27 ± 7.2 x 106 cells kg-'). There were no a
significant differences between the two treatment groups in
terms of days of neutropenia, days of thrombocytopenia,
febrile days or days on antibiotics (Table II). On average, the
patients who received filgrastim stayed in hospital longer
than those who did not, but this difference did not reach
statistical significance (mean 20.6 days vs 17.1 days, 95% CI
for difference between median number of in-patient days
-3.00 to 9.00, Mann-Whitney U-test, P-value 0.58). The
U
administration of fligrastim approximately doubled the
average overall cost of the procedure inthose patients receiv-
ing filgrastim following PBSC transfusion.
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Although this is a small study, the results suggest that the
administration of filgrastim after PBSC transfusion fails to
further accelerate haemopoietic reconstitution, reduce the
morbidity of the procedure or reduce the duration of hos-
pitalisation. Importantly, its use significantly increases the
cost of the procedure. The failure offilgrastim to significantly
accelerate neutrophil recovery contradicts the results of
Spitzer et al. (1993), who studied a similar number of
patients but found that a combination of G-CSF and GM-
CSF encouraged earlier neutrophil recovery. However, the
authors found that administration of growth factors after
PBSC infusion made no difference to the duration of hospital
stay or fever, results that concur with the findings in our
study. The authors make no comment on the use of anti-
biotics or cost of the procedure. So far there have been no
published randomised studies comparing haemopoietic recon-
stitution following high-dose chemotherapy and PBSC res-
cue, with and without myeloid growth factors. Although a
relatively small number of patients were included in our
analysis, important conclusions can be drawn. The failure of
filgrastim to further accelerate myeloid reconstitution after
high-dose chemotherapy and PBSC reinfusion resulted in
similar morbidity, number of febrile days and antibiotic use
in the two groups of patients (Table II). Although most
patients receiving filgrastim received fewer CFU-GM cells, all
patients received numbers in excess of threshold values which
produce optimal times to haemopoietic reconstitution. Our
data failed to establish any correlation between numbers of
CFU-GM cells reinfused above this level and the rate of
subsequent haemopoietic reconstitution.
There are obvious differences between the cost of the
procedure in the two treatment cohorts. The overall cost of
the procedure was calculated by adding costs of antibiotics,
conditioning chemotherapy and cost of filgrastim to the bed
cost per day of the in-patient stay after PBSC reinfusion. The
major difference in cost of the procedure was due to the
administration of filgrastim, which doubled procedural
expense in the group receiving filgrastim after PBSC rein-
fusion. The period of hospitalisation and intensive support
after myeloablative therapy was not influenced by the
administration of CSFs. This study fails to support the value
of routine administration of myeloid colony-stimulating fac-
tors after such therapy and has significant financial implica-
tions for centres carrying out high-dose chemotherapy.
Thanks to Jim Paul, CRC Clinical Trials Unit, Beatson Oncology
Centre, for invaluable statistical advice.
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